DEPLOY

Consumer model

Lingo

By Abbott · biometric

Price
$54· actual sale price
Availability
Shipping now.
Maturity
commercial
Real-world use
No verified deployments

Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.

Readiness

Lingo is shipping now at $54 (actual sale price), no capability claims are on file, the model has no verified field deployments in the registry, and no incidents are on record.

Availability
shipping-now

Shipping now.

see evidence →

Price honesty
actual-sale-price

One price on file: $54 (actual sale price).

see evidence →

Capability honesty
no-claims

No reviewed capability claims on file for Lingo.

see evidence →

Real-world use
commercial

Maturity: commercial. No verified deployments in the registry.

see evidence →

Safety record
no-incidents

No incidents on record. No verified deployments either.

What it claims to do

No reviewed capability claims on file.

Price

Real-world use

No verified deployments on file for Lingo.

Safety record

No incidents on record. No verified deployments either, so the absence is uninformative.

Privacy

No privacy practices disclosed or on file for Lingo.

Specs

notes
[{"label":"Boundary INCLUDE (narrow) - glucose-biometric + adaptive insight layer","value":"Glucose is in the biometric definition; Lingo is biometric-primary (interstitial glucose). It clears the medical-sensor-without-meaningful-AI exclusion bar on INSIGHT-LAYER substance: Lingo Count with adaptive targets, algorithm-driven personalized food-response recommendations, and Challenges are the differentiator vs a bare CGM graph (which Abbott deliberately does not sell to this wellness audience). Would it exist without the insight layer? Yes-and-meaningfully-degraded -> above the thin-AI floor. Second example of the GLUCOSE cell alongside Stelo."},{"label":"Cap-flag: NOT at Stelo parity (AI is adaptive/algorithmic, NOT verified generative)","value":"Critical distinction: Dexcom Stelo cleared the bar with a GENUINE generative-AI layer (Google Cloud Vertex AI + Gemini Weekly Insights). Lingo's primary sources describe adaptive / rule-based personalization only - no documented generative-AI layer, no 'Lingo Coach' AI agent (coaching is algorithmic plus human nutritionist via Lingo Live). Do NOT grant Lingo Stelo-equivalent AI standing. It passes on insight-layer substance, not on generative-AI grounds; this is the borderline case of the cohort and is flagged as such."},{"label":"FDA anchor","value":"FDA 510(k) K233655 decided May 29 2024; OTC integrated CGM; adults 18+ not on insulin; explicitly not for diagnosis of any disease. Directly parallel to Stelo's OTC posture (Stelo = De Novo Mar 2024). Cleared via 510(k) (Stelo via De Novo) - both are OTC wellness clearances."},{"label":"Claimed but NOT verified","value":"Any AI comparable to Stelo's generative AI (not verified - adaptive/rule-based only); a named 'Lingo Coach' AI agent (does not exist); exact stale tier table ($49/$89 figures - verified entry is ~$54/2-week, time-sensitive); any generative-AI roadmap for Lingo (none announced, unlike Dexcom)."}]
specs
Lingo: over-the-counter continuous glucose monitor (CGM) biosensor for non-diabetic / wellness consumers, built on Abbott's FreeStyle Libre sensor platform. Disposable biosensor worn on the back of the upper arm, up to 14-day wear, glucose-oxidase amperometric assay. FDA 510(k) K233655 decided May 29 2024 (announced Jun 10 2024); Class II integrated CGM (21 CFR 862.1355); indication: adults 18+ NOT on insulin; explicitly NOT for diagnosis of any disease including diabetes. App: real-time glucose graph, 'Lingo Count' daily glucose-spike metric with adaptive targets, food/activity logging, algorithm-driven personalized recommendations, 'Lingo Challenges' behavioral nudges, and 'Lingo Live' (free ~30-min sessions with human Abbott nutritionists). Pricing: entry ~$54 for a 2-week single-biosensor starter plan, recurring biweekly/monthly multi-sensor tiers. Maker: Abbott (NYSE: ABT), Abbott Diabetes Care.
formFactor
biometric (biometric-primary GLUCOSE biosensor / OTC continuous glucose monitor + adaptive insight layer; second glucose example alongside Stelo)

What's under the hood

No brain on file for Lingo.

Frequently asked questions

Is the Lingo actually available for purchase?
Yes, shipping now.Source: Abbott receives FDA clearance for two OTC CGM systems (Lingo + Libre Rio; FDA 510(k) K233655 decided May 29 2024; adults 18+ not on insulin)
What does the Lingo cost?
Lingo costs $54 one-time (actual sale price).Source: Abbott (Lingo)
Where is the Lingo being used?
No verified field deployments on record.
Is the Lingo safe?
No incidents on record, but with no verified field deployments either, the absence is uninformative.
How does the Lingo handle privacy?
No privacy practices disclosed or on file for Lingo.
Who makes the Lingo?
Lingo is made by Abbott, based in Abbott Park, Illinois, USA.Source: Abbott receives FDA clearance for two OTC CGM systems (Lingo + Libre Rio; FDA 510(k) K233655 decided May 29 2024; adults 18+ not on insulin)

Manufacturer

Abbott (registry record: /companies/abbott)

Compared to

Sources

  1. Abbott receives FDA clearance for two OTC CGM systems (Lingo + Libre Rio; FDA 510(k) K233655 decided May 29 2024; adults 18+ not on insulin) · https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-FDA-Clearance-for-Two-Over-the-Counter-Continuous-Glucose-Monitoring-Systems
  2. FDA 510(k) K233655: OTC integrated continuous glucose monitoring system (Class II, 21 CFR 862.1355; adults 18+ not on insulin; not for diagnosis of any disease) · https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233655
  3. Lingo biosensor + app (Lingo Count adaptive metric, personalized recommendations, Lingo Challenges; 14-day biosensor; entry $54 / 2-week plan; Lingo Live = human nutritionist sessions) · https://www.hellolingo.com/

Machine-readable: this page as markdown.

Canonical: https://deploy.report/models/abbott-lingo